Paul Jourdan, Amati Global Investors' chief executive, believes the UK might see a real biotech investment boom from work undertaken to tackle the coronavirus outbreak.
Amati runs two funds, a general fund for companies below FTSE 100 level and an AIM-focused VCT (LON:AMAT).
The disciplines of running a VCT have taught the fund the virtue of being long term investors in businesses, he says, and in the biotech arena that is paying off as some of its investments are at the forefront of the coronavirus fight.
Oxford Biomedica is providing manufacturing support to the Oxford Jenner Initiative to find a vaccine, for example.
Synairgen (LON:SNG) is working on a treatment to alleviate the symptoms of severe coronavirus sufferers, while Fusion Antibodies has started a research project using its humanised antibodies to find a treatment.
“The risks of being out of the market currently are as great as being in it,” he says.
